Language
English
Publication Date
6-20-2025
Journal
Journal of Clinical Oncology
DOI
10.1200/JCO-24-02057
PMID
40367400
PMCID
PMC12170155
PubMedCentral® Posted Date
6-20-2026
PubMedCentral® Full Text Version
Author MSS
Abstract
The MD Anderson dose-escalated, hypofractionated prostate radiation study was a phase III randomized trial comparing conventionally fractionated intensity-modulated radiation therapy (CIMRT, 75.6Gy in 1.8-Gy fractions) to dose-escalated, hypofractionated intensity-modulated radiation (HIMRT, 72Gy in 2.4-Gy fractions) in patients with localized prostate cancer, predominantly low and intermediate risk disease. The initial publication highlighted statistically fewer treatment failures in the HIMRT arm. We present long-term updated 13-year outcomes to determine whether cancer control benefit was maintained and to evaluate distant metastases post-hoc. With a median follow-up of 13.2 years (interquartile range, 8.8-15.9 years), treatment failure occurred less frequently in men undergoing HIMRT (n=13) compared to CIMRT (n=22) , although the difference no longer meets statistical significance (P= 0.08). Distant metastases were rare and no statistically significant difference was noted (P=0.2). There remained no statistically significant difference in late gastrointestinal 2+ (10-year 10% HIMRT vs 4% CIMRT, P=0.09) or genitourinary grade 2+ toxicity (10-year 26% vs 23%, P=0.5).
Keywords
Humans, Male, Prostatic Neoplasms, Radiation Dose Hypofractionation, Aged, Radiotherapy, Intensity-Modulated, Prospective Studies, Middle Aged, Dose Fractionation, Radiation
Published Open-Access
yes
Recommended Citation
Hassanzadeh, Comron; Kuban, Deborah; Pasyar, Sarah; et al., "Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial" (2025). Faculty, Staff and Students Publications. 8170.
https://digitalcommons.library.tmc.edu/baylor_docs/8170